InMode Ltd. (INMD)$13.74
Market Cap: 868.09 MCurrency: USD
Research Snapshot
Static fundamentals, valuation context, and investor signals for InMode Ltd. (INMD).
HEALTHCARE
MEDICAL DEVICES
DCF ready
Valuation
6.7x
EV/FCF, 14.9% FCF yield
Quality
13.7%
ROIC, 22.7% FCF margin
Growth
12.4%
5Y sales (revenue) CAGR
Balance sheet
0.0x
Debt/equity, 9.9x current ratio
Superinvestors
0
No tracked positions
Strengths to research
- Revenue compounded at 12.4% over five years.
- Free cash flow margin is healthy at 22.7%.
- Debt/equity looks manageable at 0.0x.
- 9 annual periods are available for trend analysis.
Watchouts
No major valuation, balance sheet, or growth watchouts were detected by the static screen.
Annual data: 9 periods
Quarterly data: 5 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for INMD.
Grade C
62
/ 100
Peer Comparison
Target stock against 8 market-cap comparable peers.
Heat map: red worst to green best
| INMD Target | InMode Ltd. | $868.1M | 9.6x | 6.7x | 13.7% | 12.4% | 22.7% | 78.5% | -3.5x | N/A |
| AORT | Artivion Inc. | $1.0B | 107.0x | 1388.5x | 1.5% | 11.8% | 0.2% | 64.4% | 2.7x | N/A |
| IART | Integra LifeSciences Holdings | $1.0B | -2.2x | -48.9x | -29.2% | 3.6% | -1.9% | N/A | N/A | N/A |
| AHCO | AdaptHealth Corp. | $1.2B | -20.1x | 12.8x | -2.2% | 25.2% | 6.8% | N/A | 3.4x | N/A |
| LAB | Standard Biotools Inc | $435.8M | -5.1x | -3.8x | -17.7% | -9.2% | -96.9% | 49.9% | N/A | N/A |
| QDEL | QuidelOrtho Corp. | $1.9B | -0.7x | -53.0x | -24.5% | 10.4% | -3.0% | N/A | N/A | N/A |
| ENOV | Enovis Corp. | $2.0B | -1.2x | 161.2x | -42.5% | 14.9% | 0.9% | 59.8% | 5.7x | N/A |
| LIVN | LivaNova PLC | $2.0B | -16.6x | 9.9x | -15.4% | 8.2% | 12.5% | 67.7% | -1.1x | N/A |
| ITGR | Integer Holdings Corp. | $4.1B | 30.9x | 49.8x | 3.5% | 11.5% | 5.7% | 27.0% | 3.3x | N/A |
Financial Charts
No financial data available for INMD (annual).